S. Grant

D. Conrad, H. Bear, S. Grant, 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors

John D. Roberts, M. Gonen, G. Schwartz, 2011, Investigational New Drugs.

Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells

D. Häussinger, P. Dent, A. Yacoub, 2010, Molecular Cancer Therapeutics.

Discovery afenib Activates CD 95 and Promotes Autophagy and Cell Ther th via Src Family Kinases in Gastrointestinal Tumor Cells

D. Häussinger, P. Dent, A. Yacoub, 2010 .

Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation

John D. Roberts, P. Fisher, P. Dent, 2008, Clinical Cancer Research.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

Derick R. Peterson, J. Armitage, J. Vose, 2011, Blood.

lymphoma patients with relapsed/refractory indolent and mantle cell non-Hodgkin The combination of bendamustine, bortezomib, and rituximab for

J. Vose, R. Fisher, S. Grant, 2011 .

Induced G 2 M Arrest and Attenuates Mitochondrial Injury and Apoptosis in p53-Null Human Leukemia Cells

P. Dent, S. Grant, M. Rahmani, 2004 .

Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24–mediated toxicity

P. Fisher, John Calvin Reed, P. Dent, 2011, Proceedings of the National Academy of Sciences.

Inhibition of MCL-1 enhances Lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy

K. Nephew, P. Dent, S. Grant, 2009, Cancer biology & therapy.

Dysregulation of the Cyclin-dependent Kinase Inhibitor p21 the Susceptibility of Human Leukemia Cells (U937) to 1- b - D -Arabinofuranosylcytosine-mediated Mitochondrial Dysfunction and Apoptosis 1

P. Fisher, D. Conrad, P. Dent, 1999 .

Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).

A. Saunders, S. Grant, S. Chellappan, 1998, Differentiation; research in biological diversity.

Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60)

S. Grant, S. Chellappan, P. Fisher, 1997, Leukemia.

Targeting the regulatory machinery of BIM for cancer therapy.

S. Grant, H. Harada, 2012, Critical reviews in eukaryotic gene expression.

Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies

S. Grant, B. Holkova, 2011, Expert review of hematology.

resistant to STI 571 cells sensitive and + deacetylase inhibitors to induce apoptosis in Bcr / Abl

D. Conrad, P. Dent, S. Grant, 2003 .

Coadministration of UCN-01 with MEK1/2 Inhibitors Potently Induces Apoptosis in

P. Dent, S. Grant, Chunrong Yu, 2002, Cancer biology & therapy.

CellsSynergistically Induces Apoptosis in Human Leukemia Suberoylanilide Hydroxamic Acid or Sodium Butyrate 17-Allylamino-17-demethoxygeldanamycin with Coadministration of the Heat Shock Protein 90 Antagonist Updated

P. Dent, S. Grant, M. Rahmani, 2003 .

A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.

Barbara S. Paugh, S. Milstien, S. Spiegel, 2008, Blood.

Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells

John D. Roberts, P. Fisher, P. Dent, 2007, Molecular Cancer Therapeutics.

Atg7 in AML: a double-edged sword?

S. Grant, 2016, Blood.

PERK-dependent regulation of HSP70 expression and the regulation of autophagy

P. Fisher, C. Chen, P. Dent, 2008, Autophagy.

OSU-03012 stimulates PERK-dependent increases in HSP 70 expression , attenuating its lethal actions in transformed cells

P. Fisher, S. Spiegel, C. Chen, 2007 .

Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95

P. Fisher, P. Dent, M. Hagan, 2008, Molecular Cancer Therapeutics.

Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic.

P. Fisher, P. Dent, S. Grant, 2011, Discovery medicine.

Enhanced delivery of mda‐7/IL‐24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the apogossypol derivative BI‐97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells

P. Fisher, John Calvin Reed, P. Dent, 2012, Journal of cellular physiology.

New agents for AML and MDS.

S. Grant, 2009, Best practice & research. Clinical haematology.

mda‐7/IL‐24 differentially regulates soluble and nuclear clusterin in prostate cancer

P. Fisher, P. Dent, S. Grant, 2012, Journal of cellular physiology.

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

P. Dent, S. Grant, Yun Dai, 2011, Blood.

Cytokinetically quiescent ( G 0 / G 1 ) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk 1 and MEK 1 / 2

P. Dent, S. Grant, Yun Dai, 2011 .

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

P. Dent, S. Grant, Yun Dai, 2008, Blood.

Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway*

P. Fisher, P. Atadja, P. Dent, 2010, The Journal of Biological Chemistry.

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.

P. Dent, S. Grant, Yun Dai, 2007, Blood.

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation

John D. Roberts, S. Grant, D. Spicer, 2000, Cancer Chemotherapy and Pharmacology.

Chemical Therapeutics The Novel Chk 1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

S. Grant, Yun Dai, Hui Lin, 2013 .

Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.

P. Fisher, P. Dent, A. Yacoub, 2010, Cancer research.

PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells

P. Fisher, S. Spiegel, P. Dent, 2008, Autophagy.

Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells

P. Fisher, S. Spiegel, P. Dent, 2008, Molecular Cancer Therapeutics.

Pharmacological Inhibitors of Protein Kinase C HL-60 Human Promyelocytic Leukemia Cells by Induction of Apoptotic DNA Fragmentation and Cell Death in Updated

Lawrence, S. Grant, W. Jarvis, 2006 .

Granulocyte-Macrophage Colony-Stimulating Factor / Interleukin-3 Fusion Protein ( PIXY 321 ) Enhances High-Dose AraC-Induced Programmed Cell Death or Apoptosis in Human Myeloid Leukemia Cells

A. M. Ibrado, S. Grant, M. Hughes, 2003 .

Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).

S. Grant, É. Szabó, W. Jarvis, 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway.

S. Grant, D. Gewirtz, R. Kolesnick, 1994, Proceedings of the National Academy of Sciences of the United States of America.

The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress.

S. Grant, R. Rosato, E. Battaglia, 2004, International journal of oncology.

Primary Human Glioblastoma Multiforme Cells Induced Killing of −-7 / IL-24 mda Thioredoxin Play a Key Role in Dependent Regulation of Ceramide Synthase 6 and −

P. Fisher, S. Spiegel, P. Dent, 2010 .

Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells.

S. Grant, D. Gewirtz, R. Kolesnick, 1994, The Journal of biological chemistry.

Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.

S. Grant, L. Povirk, D. Gewirtz, 1994, Biochemical pharmacology.

multiple myeloma through a novel link between autophagy and apoptosis A Bim-targeting strategy overcomes adaptive bortezomib-resistance in

S. Grant, Richard J. Jones, R. Orlowski, 2014 .

Contribution of Disruption of the Nuclear Factor-κB Pathway to Induction of Apoptosis in Human Leukemia Cells by Histone Deacetylase Inhibitors and Flavopiridol

P. Dent, S. Grant, N. Gao, 2004, Molecular Pharmacology.

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

John D. Roberts, G. Shapiro, S. Grant, 2008 .

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)

S. Grant, R. Rosato, J. Almenara, 2002, Leukemia.

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

John D. Roberts, D. Coppola, S. Grant, 2011, Clinical Cancer Research.

High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.

K. Bhalla, A. M. Ibrado, S. Grant, 1993, Blood.

Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose Ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells.

K. Bhalla, A. M. Ibrado, S. Grant, 1992, Blood.

Protein Kinase C-dependent Activation of the Tumor Necrosis Factor Receptor-mediated Extrinsic Cell Death Pathway Underlies Enhanced Apoptosis in Human Myeloid Leukemia Cells Exposed to Bryostatin 1 and Flavopiridol1

P. Dent, S. Grant, L. Cartee, 2003 .

Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.

P. Dent, S. Grant, L. Cartee, 2003, Molecular cancer therapeutics.

Conjugated Bile Acids Regulate Hepatocyte Glycogen Synthase Activity In Vitro and In Vivo via Gαi Signaling

P. Dent, S. Grant, W. Pandak, 2007, Molecular Pharmacology.

Targeting Mcl-1 for the therapy of cancer

P. Fisher, John Calvin Reed, P. Dent, 2011, Expert opinion on investigational drugs.

The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.

S. Grant, L. Cartee, R. Rosato, 2002, Molecular cancer therapeutics.

Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.

S. Grant, Z. Wang, L. Kramer, 1996, Experimental cell research.

MEK1/2 inhibitors promote Ara-C-induced apoptosis but not loss of Deltapsi(m) in HL-60 cells.

P. Dent, S. Grant, Z. Wang, 2001, Biochemical and biophysical research communications.

In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.

S. Grant, L. Boise, E. Westin, 1991, Biochemical Pharmacology.

Effects of bryostatin 1 and rGM‐CSF on the metabolism of 1‐β‐d‐arabinofuranosylcytosine in human leukaemic myeloblasts

S. Grant, W. Jarvis, A. Turner, 1992, British journal of haematology.

Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.

D. Conrad, P. Dent, S. Grant, 2004, Blood.

Interruption of the NF-B pathway by Bay 11-7082 promotes UCN-01 – mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells

D. Conrad, P. Dent, S. Grant, 2003 .

therapeutic targets in human leukemia A selective sphingosine kinase 1 inhibitor integrates multiple molecular

Barbara S. Paugh, S. Milstien, S. Spiegel, 2013 .

Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation.

P. Dent, J. Park, S. Grant, 1999, The Journal of pharmacology and experimental therapeutics.

Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.

G. Schwartz, P. Dent, S. Grant, 1998, Molecular pharmacology.

Positive and negative regulation of JNK1 by protein kinase C and p42MAP kinase in adult rat hepatocytes

P. Dent, R. Mikkelsen, S. Grant, 1997 .

Induction of Apoptosis and Potentiation of Ceramide-mediated Cytotoxicity by Sphingoid Bases in Human Myeloid Leukemia Cells (*)

S. Grant, F. Fornari, Lora B. Kramer, 1996, The Journal of Biological Chemistry.

oxygen species (ROS)-dependent mechanism inhibitors to induce apoptosis in human leukemia cells through a reactive The tyrphostin adaphostin interacts synergistically with proteasome

P. Dent, S. Grant, M. Rahmani, 2013 .

The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.

P. Dent, S. Grant, M. Rahmani, 2006, Blood.

Multiple Cyclin Kinase Inhibitors Promote Bile Acid-induced Apoptosis and Autophagy in Primary Hepatocytes via p53-CD95-dependent Signaling*

P. Fisher, P. Dent, S. Grant, 2008, Journal of Biological Chemistry.

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

P. Dent, S. Grant, Chunrong Yu, 2005, Leukemia.

A Serotype 5/3 Adenovirus Expressing MDA-7/IL-24 Infects Renal Carcinoma Cells and Promotes Toxicity of Agents That Increase Ros and Ceramide Levels

P. Fisher, S. Spiegel, P. Dent, 2011, Molecular Pharmacology.

Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling

P. Fisher, P. Dent, A. Yacoub, 2008, Molecular Cancer Therapeutics.

Low-Dose BBR3610 Toxicity in Colon Cancer Cells Is p53-Independent and Enhanced by Inhibition of Epidermal Growth Factor Receptor (ERBB1)-Phosphatidyl Inositol 3 Kinase Signaling

John D. Roberts, P. Fisher, P. Dent, 2007, Molecular Pharmacology.

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

P. Dent, S. Grant, C. Yu, 2016, Leukemia.

Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1

S. Grant, Z. Wang, J. Vrana, 1999, Leukemia.

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.

S. Grant, J. Leverson, M. Rahmani, 2018, Cancer research.

Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts.

K. Bhalla, A. M. Ibrado, S. Grant, 1991, Blood.

The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo

S. Grant, Liang Zhou, M. Kmieciak, 2019, Clinical Cancer Research.

Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts

K. Bhalla, A. M. Ibrado, S. Grant, 1991 .

CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.

P. Dent, S. Grant, R. Orlowski, 2012, Cancer research.

Enhancing venetoclax activity in hematological malignancies

S. Grant, Toshihisa Satta, 2020, Expert opinion on investigational drugs.

Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor.

S. Grant, F. Li, G. Pettit, 1992, Blood.

An Intact NF-kappaB Pathway is Required for Histone Deacetylase Inhibitor Induced G1 Arrest and Maturation in U937 Human Myeloid Leukemia Cells

S. Grant, M. Rahmani, Yun Dai, 2003, Cell cycle.

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

John D. Roberts, D. Coppola, S. Grant, 2014, Clinical Cancer Research.

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.

John D. Roberts, B. Druker, S. Grant, 2005 .

IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF- k B – and caspase-8 – dependent mechanisms

A. Silva, S. Grant, Yun Dai, 2021 .

Recombinant human (rh)IL-4-mediated apoptosis and recombinant human IL-6-mediated protection of recombinant human stem cell factor-dependent human mast cells derived from cord blood mononuclear cell progenitors.

S. Grant, H. W. Chang, J. Kochan, 1999, Journal of immunology.

Mononuclear Cell Progenitors Mast Cells Derived from Cord Blood Human Stem Cell Factor-Dependent Human IL-6-Mediated Protection of Recombinant Apoptosis and Recombinant Human Recombinant Human ( rh ) IL-4-Mediated

S. Grant, H. Chang, Zhiliang Wang, 1999 .

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

S. Grant, M. Muschen, Yun Dai, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical HDAC Inhibitors Potentiate the Activity of the BCR / ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or-Resistant BCR / ABL þ Leukemia Cells In Vitro and In Vivo

S. Grant, M. Muschen, Yun Dai, 2011 .

Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells

P. Dent, A. Yacoub, S. Grant, 2012, Cancer biology & therapy.

Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study

John D. Roberts, S. Grant, E. Rubin, 2004, Investigational New Drugs.

Role of protein kinase C in phosphorylation of vinculin in adriamycin-resistant HL-60 leukemia cells.

K. D. Hartman, R. Glazer, S. Grant, 1988, Cancer research.

Isolation and Characterization of an Anthracycline-resistant Human Leukemic Cell Line1

K. Bhalla, S. Grant, A. Hindenburg, 2006 .

Isolation and Characterization of an Anthracycline-resistant Human Leukemic Cell Line 1

K. Bhalla, S. Grant, A. Hindenburg, 2006 .

Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin

S. Grant, D. Gewirtz, S. Yanovich, 2004, Cancer Chemotherapy and Pharmacology.

Characterization of the cell surface receptors for human B cell growth factor of 12,000 molecular weight.

S. Grant, S. Mehta, A. Maizel, 1986, Journal of immunology.

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies

John D. Roberts, S. Grant, J. Karp, 2012, Cancer Chemotherapy and Pharmacology.

Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma

John D. Roberts, W. H. Carter, M. Millenson, 2006, Clinical Cancer Research.

Antibody Antagonist: Preclinical Efficacy A Monovalent Anti-Human CD28 Domain

P. M. Davis, S. Grant, J. Bryson, 2017 .

A Monovalent Anti-Human CD28 Domain Antibody Antagonist: Preclinical Efficacy and Safety

P. M. Davis, S. Grant, J. Bryson, 2013, The Journal of Immunology.

The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells

M. Copland, S. Grant, G. Helgason, 2011, Leukemia.

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

S. Grant, G. Simmons, P. Bose, 2013, Expert opinion on investigational drugs.

Apoptosis regulators.

S. Grant, H. Harada, 2003, Reviews in clinical and experimental hematology.

IN VITRO AND IN VIVO INTERACTIONS BETWEEN THE HDAC6 INHIBITOR RICOLINOSTAT (ACY1215) AND THE IRREVERSIBLE PROTEASOME INHIBITOR CARFILZOMIB IN NON-HODGKIN’S LYMPHOMA CELLS

S. Grant, S. Quayle, G. Dasmahapatra, 2014 .

CD 38 expression may vary during the course of the disease independent prognostic variables in chronic lymphocytic leukemia , but CD 38 expression and immunoglobulin variable region mutations are

E. Solary, S. Grant, M. Fontenay, 2002 .

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

John D. Roberts, G. Garcia-Manero, S. Grant, 2011 .

Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc.

S. Grant, S. Wu‐Pong, W. Jarvis, 1997, Biochemical pharmacology.

Bryostatin-1 Specifically Inhibits In Vitro IgE Synthesis1

D. Conrad, S. Grant, D. Rabah, 2001, The Journal of Immunology.

Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF‐κB and Bim

P. Dent, S. Grant, Yun Dai, 2011, British journal of haematology.

Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.

P. Fisher, K. Shah, P. Dent, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis.

I. Tomlinson, S. Grant, I. Roitt, 2007, The Journal of infectious diseases.

Cotargeting survival signaling pathways in cancer.

S. Grant, 2008, The Journal of clinical investigation.

mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity.

P. Fisher, P. Dent, A. Yacoub, 2010, Cytokine & growth factor reviews.

Targeting leukemia stem cells with HDAC inhibitors and modulators of the DNA damage response.

S. Grant, 2014, Leukemia supplements.

PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

P. Dent, S. Grant, Yun Dai, 2013, Cancer biology & therapy.

Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24

P. Fisher, P. Dent, S. Grant, 2009, Cancer biology & therapy.

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

S. Grant, D. Sullivan, Yun Dai, 2016, Oncotarget.

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

S. Grant, W. Dalton, D. Sullivan, 2016, Journal of Hematology & Oncology.

Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase.

S. Grant, Haeseong Park, P. Bose, 2013, Leukemia research reports.

Effects of pyrimidine antagonists on sialic acid regeneration in HL-60 cells.

S. Grant, A. Hindenburg, R. Taub, 1985, Cancer research.

Effect of / V-( Phosphonacetyl )-i _-aspartate on 5-Azacytidine Metabolism in P 388 and L 1210 Cells 1

S. Grant, F. Rauscher, A. Jakubowski, 2006 .

Biochemical Modulation as a Guide to Rational Combination Chemotherapy for the Treatment of Cancer

C. Benz, S. Grant, E. Cadman, 1983 .

Altered 5-azacytidine metabolism following 3-deazauridine treatment of L5178Y and human myeloblasts.

S. Grant, E. Cadman, 1980, Cancer research.

Cancer Therapy : Preclinical PLK 1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate – Sensitive or – Resistant BCR / ABL þ Leukemia Cells In Vitro and In Vivo

S. Grant, Elisa Attkisson, G. Dasmahapatra, 2013 .

PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

S. Grant, Elisa Attkisson, G. Dasmahapatra, 2012, Clinical Cancer Research.

Reducing cholesterol and overcoming drug resistance

S. Grant, 2004 .

An Anti‐CD154 Domain Antibody Prolongs Graft Survival and Induces Foxp3+ iTreg in the Absence and Presence of CTLA‐4 Ig

A. Yamniuk, S. Grant, S. Nadler, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

P. Dent, S. Grant, L. Cartee, 2003 .

Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.

P. Dent, S. Grant, L. Cartee, 2002, Molecular pharmacology.

Nonlinear response surface in the study of interaction analysis of three combination drugs

Shumei S. Sun, J. Birch, M. Tan, 2017, Biometrical journal. Biometrische Zeitschrift.

Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells

S. Grant, R. Orlowski, Yun Dai, 2014, PloS one.

Phosphodiesterase 5 Inhibitors Enhance Chemotherapy Killing in Gastrointestinal/Genitourinary Cancer Cells

P. Fisher, P. Dent, S. Grant, 2014, Molecular Pharmacology.

Interaction Analysis of Three Combination Drugs via a Modified Genetic Algorithm

Shumei S. Sun, J. Birch, M. Tan, 2014 .

Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

Derick R. Peterson, J. Friedberg, R. Fisher, 2012, Molecular Cancer Therapeutics.

Preclinical Development Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Car fi lzomib in GC-and ABC-DLBCL Cells In Vitro and In Vivo

Derick R. Peterson, J. Friedberg, R. Fisher, 2012 .

Potentiation of the Activity of l-ÃŸ-o-Arabinofuranosylcytosine by the Protein Kinase C Activator Bryostatin 1 in HL-60 Cells: Association with Enhanced Fragmentation of Mature DNA1

P. Lin, S. Grant, D. Gewirtz, 2006 .

Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21CIP1/WAF1 induction rather than AKT inhibition

P. Dent, S. Grant, M. Rahmani, 2003, Oncogene.

The Histone Deacetylase Inhibitor Sodium Butyrate Interacts Synergistically with Phorbol Myristate Acetate (PMA) to Induce Mitochondrial Damage and Apoptosis in Human Myeloid Leukemia Cells through a Tumor Necrosis Factor-α-Mediated Process

S. Grant, M. Rahmani, Yun Dai, 2002 .

Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.

P. Dent, S. Grant, R. Decker, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Regulation of p21 and p27 expression by the hepatitis B virus X protein and the alternate initiation site X proteins, AUG2 and AUG3

P. Fisher, P. Dent, S. Grant, 2003, Journal of gastroenterology and hepatology.

Phase Ib trial of bryostatin 1 in patients with refractory malignancies.

H. Bear, S. Grant, E. Poplin, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity.

K. Bhalla, S. Grant, Z. Arlin, 1987, Blood.

Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors.

S. Grant, F. Rauscher, E. Cadman, 1982, Cancer research.

Effects of the protein kinase C stimulant bryostatin 1 on the proliferation and colony formation of irradiated human T-lymphocytes.

R. Schmidt-Ullrich, P. Lin, S. Grant, 1994, International journal of radiation biology.

The macrocyclic lactone protein kinase C activator, bryostatin 1, either alone, or in conjunction with recombinant murine granulocyte-macrophage colony-stimulating factor, protects Balb/c and C3H/HeN mice from the lethal in vivo effects of ionizing radiation.

P. Lin, S. Grant, G. Pettit, 1994, Blood.

Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis

L. Zon, S. Grant, M. Birrer, 1996, Nature.

Enhancing proteotoxic stress as an anticancer strategy

S. Grant, 2011, Oncotarget.

Isolation and Characterization of a Deoxycytidine Kinase-deficient Human Promyelocyte Leukemic Cell Line Highly Resistant to 1-β-D- Arabinofuranosylcytosine

K. Bhalla, S. Grant, R. Nayak, 1984 .

Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.

Derick R. Peterson, S. Grant, Yun Dai, 2015, Experimental hematology.

ATRA and ATO team up against NPM1.

S. Grant, 2015, Blood.

A human domain antibody and Lewis b glycoconjugate that inhibit binding of Helicobacter pylori to Lewis b receptor and adhesion to human gastric epithelium.

S. Grant, C. Kelly, I. Roitt, 2009, The Journal of infectious diseases.

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

John D. Roberts, S. Grant, H. Sankala, 2014 .

Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts).

S. Grant, M. Egorin, J. Wright, 2007 .

survivin-dependent mechanism for survival and − reveals a heat-shock protein TEL / AML 1 RNAi-mediated silencing of

E. Solary, S. Grant, M. Fontenay, 2006 .

Abstract 2686: The CDK inhibitor dinaciclib (SCH727965) inhibits the unfolded protein response (UPR) through a CDK1- and CDK5-dependent mechanism

S. Grant, Tri K. Nguyen, 2014 .

Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism

S. Grant, Tri K. Nguyen, 2013, Molecular Cancer Therapeutics.

Enhancement of 1-beta-D-arabinofuranosylcytosine accumulation within L1210 cells and increased cytotoxicity following thymidine exposure.

S. Grant, E. Cadman, C. Lehman, 1980, Cancer research.

Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors

S. Grant, 2011, Leukemia & lymphoma.

Preclinical Development Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

J. Friedberg, R. Fisher, P. Dent, 2011 .

HDAC inhibitors repress the polycomb protein BMI1

S. Grant, 2010, Cell cycle.

Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.

S. Grant, R. Rosato, Chunrong Yu, 2004, Molecular pharmacology.

Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).

S. Grant, R. Rosato, R. Gopalkrishnan, 2001, International journal of oncology.

Bile Acid Regulation of C/EBPβ, CREB, and c-Jun Function, via the Extracellular Signal-Regulated Kinase and c-Jun NH2-Terminal Kinase Pathways, Modulates the Apoptotic Response of Hepatocytes

P. Dent, K. Valerie, G. Amorino, 2003, Molecular and Cellular Biology.

Isolation and characterization of an anthracycline-resistant human leukemic cell line.

K. Bhalla, S. Grant, A. Hindenburg, 1985, Cancer research.

Dendritic cell-derived IL 2 production is regulated by IL 15 both in humans and mice

E. Solary, S. Grant, M. Fontenay, 2004 .

3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.

Hardik I. Parikh, G. Kellogg, S. Grant, 2012, European journal of medicinal chemistry.

Downregulation of δ CaM kinase II in human tumor cells

R. Mikkelsen, S. Grant, W. Jarvis, 1999 .

Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.

K. Valerie, S. Grant, É. Szabó, 1996, Molecular pharmacology.

Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.

P. Dent, S. Grant, Chunrong Yu, 2001, Cancer research.

Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade.

S. Grant, J. Vrana, 2001, Blood.

Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy.

S. Grant, W. Jarvis, S. Grant, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Resveratrol Sensitizes Acute Myelogenous Leukemia Cells to Histone Deacetylase Inhibitors through Reactive Oxygen Species-Mediated Activation of the Extrinsic Apoptotic Pathway

P. Dent, S. Grant, R. Rosato, 2012, Molecular Pharmacology.

Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action.

P. Dent, S. Grant, Steven Grant, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Histone deacetylase inhibitors in clinical development

S. Grant, R. Rosato, 2004, Expert opinion on investigational drugs.

Ara-C: cellular and molecular pharmacology.

S. Grant, S. Grant, 1998, Advances in cancer research.

PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells

M. Malkin, P. Dent, S. Grant, 2014, Cancer biology & therapy.

Hepatitis B virus X protein increases expression of p21Cip‐1/WAF1/MDA6 and p27Kip‐1 in primary mouse hepatocytes, leading to reduced cell cycle progression

P. Fisher, P. Dent, A. Yacoub, 2001 .

Characterization of compounds shed from the surface of human leukemic myeloblasts in vitro.

S. Grant, T. Mohanakumar, D. Roncari, 1982, Blood.

Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.

Paul Dent, P. Fisher, P. Dent, 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells.

K. Bhalla, S. Grant, P. Swerdlow, 1991, Blood.

Development of Protein Kinase C and Cyclin-Dependent Kinase Inhibitors As Potentiators of Cytotoxic Drug Action in Leukemia

S. Grant, 2005 .

Isolation and Characterization of a Deoxycytidine Kinase-deficient Human Promyelocytic Leukemic Cell Line Highly Resistant to 1-/Ã–-D-Ara binof ura nosy Icy tosine1

K. Bhalla, S. Grant, R. Nayak, 2006 .

Isolation and Characterization of a Deoxycytidine Kinase-deficient Human Promyelocytic Leukemic Cell Line Highly Resistant to 1-/ Ã –-DAra binof ura nosy Icy tosine 1

K. Bhalla, S. Grant, R. Nayak, 2006 .

Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine.

P. Dent, S. Grant, Z. Wang, 2000, Differentiation; research in biological diversity.

Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C.

S. Grant, L. Povirk, W. Jarvis, 1994, Cancer research.

Correction to: “Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment”

John D. Roberts, P. Fisher, P. Dent, 2016, Molecular Pharmacology.

Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation

P. Fisher, P. Dent, M. Hagan, 2008, Molecular Pharmacology.

Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.

P. Dent, S. Grant, H. Harada, 2007, Cancer research.

Biochemical modulation of cytosine arabinoside.

S. Grant, S. Grant, 1990, Pharmacology & therapeutics.

2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity.

K. Bhalla, S. Grant, D. Volsky, 1989, Blood.

Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis

K. Bhalla, S. Grant, 1987, Cancer Chemotherapy and Pharmacology.

The effect in vitro of 2'-deoxycytidine on the metabolism and cytotoxicity of 2',3'-dideoxycytidine

K. Bhalla, S. Grant, D. Volsky, 1990, AIDS.

Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis.

S. Grant, R. Decker, Yun Dai, 2003, Biochemical pharmacology.

Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.

K. Bhalla, S. Grant, C. McCrady, 1991, Leukemia research.

Dose- and schedule-dependent activation and drug synergism between thymidine and 5-aza-2'-deoxycytidine in a human promyelocytic leukemia cell line.

S. Grant, F. Rauscher, E. Cadman, 1982, Cancer research.

Modulation of ara-C induced apoptosis in leukemia by the PKC activator bryostatin 1.

S. Grant, 1997, Frontiers in bioscience : a journal and virtual library.

Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells.

K. Bhalla, S. Grant, Z. Arlin, 1987, Leukemia.

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.

S. Payne, S. Spiegel, P. Dent, 2005, Cancer research.

Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation.

P. Dent, S. Grant, J. Vrana, 1999, Radiation research.

Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma

S. Grant, R. Orlowski, Yun Dai, 2017, Oncotarget.

Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

P. Fisher, S. Spiegel, K. Ryan, 2008, Cancer biology & therapy.

MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity.

W. Linehan, P. Fisher, P. Dent, 2003, Molecular cancer therapeutics.

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

Paul Dent, Chunrong Yu, D. Conrad, 2003, Blood.

Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.

S. Grant, F. Rauscher, A. Jakubowski, 1981, Cancer research.

Synergistic interaction between acivicin (AT-125) and 6-thioguanine in the murine leukemia L1210. Biochemical and cytokinetic considerations.

K. Bhalla, S. Grant, A. Deitch, 1984, Biochemical pharmacology.

Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.

K. Bhalla, S. Grant, R. Nayak, 1984, Cancer research.

MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors

P. Fisher, K. Shah, P. Dent, 2008, Cancer biology & therapy.

PI3K: a rational target for ovarian cancer therapy?

P. Fisher, P. Dent, S. Grant, 2009, Cancer biology & therapy.

Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells

P. Dent, S. Grant, A. Poklepovic, 2015, Journal of cellular physiology.

The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation

Paul Dent, P. Dent, S. Grant, 2007, Molecular Pharmacology.

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.

Yun Dai, Hui Lin, Yu Zhang, 2014, Blood.

Enhancing CHK1 inhibitor lethality in glioblastoma

Yun Dai, Paul Dent, P. Dent, 2012, Cancer biology & therapy.

Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.

S. Grant, M. Rahmani, C. Dumur, 2015, Blood.

Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia

S. Hammond, S. P. Nana-Sinkam, S. Grant, 2010, Molecular Pharmacology.

dependent and − T cell receptor − pre-deficient T cell lymphomas through E 2 A Notch 1 promotes survival of

E. Solary, S. Grant, M. Fontenay, 2006 .

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

John D. Roberts, M. Raffeld, Hui-Yi Lin, 2015, Clinical Cancer Research.

A Phase II Trial of AZD 6244 ( Selumetinib , ARRY-142886 ) , an Oral MEK 1 / 2 Inhibitor , in Relapsed / Refractory Multiple Myeloma

John D. Roberts, M. Raffeld, Hui-Yi Lin, 2015 .

Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA

P. Fisher, P. Dent, S. Grant, 2012, Molecular Pharmacology.

Targeting multiple arms of the apoptotic regulatory machinery.

S. Grant, Yun Dai, 2007, Cancer research.

The regulation of tumor suppressor genes by oncogenes.

P. Fisher, P. Dent, S. Grant, 2003, Methods in molecular biology.

H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.

P. Dent, M. Hagan, A. Yacoub, 2005, Molecular cancer therapeutics.

CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.

Yun Dai, Paul Dent, P. Fisher, 2011, Molecular interventions.

Abl/Src inhibitor BMS-354/825 MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual

P. Dent, S. Grant, H. Harada, 2013 .

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.

P. Dent, S. Grant, H. Harada, 2007, Blood.

The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity

R. Schmidt-Ullrich, P. Dent, S. Grant, 1998, Leukemia.

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo

S. Grant, R. Orlowski, J. Leverson, 2017, British Journal of Cancer.

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway

S. Grant, R. Decker, Yun Dai, 2001, Cell Death and Differentiation.

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

S. Grant, M. Kmieciak, Elisa Hawkins, 2018, BMC Cancer.

Loss of the BCL-2 Phosphorylation Loop Domain Is Required to Protect Human Myeloid Leukemia Cells from Flavopiridol-Mediated Mitochondrial Damage and Apoptosis

P. Dent, S. Grant, R. Decker, 2002, Cancer biology & therapy.

Follicular dendritic cells protect malignant B cells from apoptosis induced by anti-Fas and antineoplastic agents.

S. Grant, M. Yang, W. Jarvis, 1999, Journal of immunology.

and Antineoplastic Agents B Cells from Apoptosis Induced by Anti-Fas Follicular Dendritic Cells Protect Malignant

S. Grant, Mingqi Yang, W. Jarvis, 1999 .

Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.

P. Dent, S. Grant, G. Krystal, 1997, Molecular pharmacology.

Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate

B. Druker, P. Dent, S. Grant, 2006, Clinical Cancer Research.

Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.

P. Dent, S. Grant, Chunrong Yu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Histone Deacetylase Inhibitors in Cancer Therapy

S. Grant, R. Rosato, 2003, Cancer biology & therapy.

Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.

D. Conrad, P. Dent, S. Grant, 2003, Cancer research.

Response and Resistance to Ionizing Radiation

P. Dent, M. Hagan, A. Yacoub, 2006 .

MAPK pathways in radiation responses

Paul Dent, P. Fisher, P. Dent, 2003, Oncogene.

The role of signal transduction pathways in drug and radiation resistance.

P. Fisher, P. Dent, S. Grant, 2002, Cancer treatment and research.

The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.

Yun Dai, S. Grant, Yun Dai, 2004, Molecular cancer therapeutics.

The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

S. Grant, R. Rosato, J. Almenara, 2003, Cancer research.

The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p 21 CIP 1 / WAF 1 1

S. Grant, R. Rosato, J. Almenara, 2003 .

PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo

J. Friedberg, S. Grant, M. Rahmani, 2014, Clinical Cancer Research.

REVIEW Signal Transduction and Cellular Radiation Responses

P. Dent, R. Mikkelsen, K. Valerie, 2000 .

Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.

Z. Su, P. Fisher, S. Grant, 1998, Experimental cell research.

Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.

D. Conrad, P. Dent, S. Grant, 1999, Cancer research.

Radiation-induced cell signaling: inside-out and outside-in

P. Fisher, P. Dent, K. Valerie, 2007, Molecular Cancer Therapeutics.

Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A.

P. Dent, S. Grant, Yun Dai, 2002, Cell cycle.

Induction of Apoptosis in Human Leukemia Cells by the CDK1 Inhibitor

P. Dent, S. Grant, Yun Dai, 2002 .

Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.

S. Grant, R. Rosato, Yun Dai, 2003, Molecular cancer therapeutics.

Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance

S. Grant, Yun Dai, 2011 .

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

Jing Wang, M. Konopleva, M. Andreeff, 2019, Haematologica.

Targeting novel signaling pathways for resistant acute myeloid leukemia.

L. Platanias, S. Grant, K. Sakamoto, 2015, Molecular genetics and metabolism.

Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL

P. Dent, S. Grant, Z. Wang, 1999, Leukemia.

Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis

John Calvin Reed, S. Grant, L. Boise, 1997, Cell Death and Differentiation.

Dissecting the Roles of Checkpoint Kinase 1/CDC2 and Mitogen-Activated Protein Kinase Kinase 1/2/Extracellular Signal-Regulated Kinase 1/2 in Relation to 7-Hydroxystaurosporine-Induced Apoptosis in Human Multiple Myeloma Cells

P. Dent, S. Grant, Weiqun Li, 2006, Molecular Pharmacology.

Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

John D. Roberts, S. Grant, Mitchell R. Smith, 2002, Clinical lymphoma.

Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine.

P. Fisher, John Calvin Reed, P. Dent, 2010, Cancer research.

Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.

P. Dent, S. Grant, M. Rahmani, 2005, Blood.

INTERRUPTION OF BOTH AKT AND MEK / ERK PATHWAYS AND ACTIVATION OF SEK 1 / JNK

P. Dent, S. Grant, M. Rahmani, 2004 .

Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.

Liang Qiao, Paul Dent, P. Dent, 2002, Frontiers in bioscience : a journal and virtual library.

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

J. Friedberg, R. Fisher, P. Dent, 2010, Leukemia research.

NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263

U. McDermott, M. Garnett, A. Dastur, 2018, Clinical Cancer Research.

Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.

S. Grant, M. Rahmani, P. Bose, 2014, Physiological genomics.

Mitochondria Leukemia T Cells Is Regulated by Translocation of Bad to 9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat ∆ Updated

M. Nagarkatti, P. Nagarkatti, S. Grant, 2006 .

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

S. Grant, Hui Lin, Haeseong Park, 2015, Leukemia research.

The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

Yun Dai, Hui Lin, S. Grant, 2013, Molecular Cancer Therapeutics.

Sorafenib/Regorafenib and Phosphatidyl Inositol 3 Kinase/Thymoma Viral Proto-Oncogene Inhibition Interact to Kill Tumor Cells

P. Dent, S. Grant, N. Cruickshanks, 2013, Molecular Pharmacology.

The Cyclin-Dependent Kinase Inhibitor p21CIP1/WAF1 Blocks Paclitaxel-Induced G2M Arrest and Attenuates Mitochondrial Injury and Apoptosis in p53-Null Human Leukemia Cells

P. Dent, S. Grant, M. Rahmani, 2004 .

Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis.

P. Dent, S. Grant, Z. Wang, 1999, Biochemical and biophysical research communications.

The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.

John D. Roberts, S. Grant, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells

P. Fisher, K. Nephew, P. Dent, 2011, Autophagy.

Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.

P. Fisher, K. Nephew, P. Dent, 2011, Cancer research.

Cyclin D1 Overexpression Increases the Susceptibility of Human U266 Myeloma Cells to CDK Inhibitors through a Process Involving p130-, p107- and E2F-Dependent S-Phase Entry

P. Dent, S. Grant, Yun Dai, 2006, Cell cycle.

OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing

P. Dent, A. Yacoub, S. Grant, 2012, Cancer biology & therapy.

Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.

P. Fisher, S. Spiegel, D. Häussinger, 2010, Cancer research.

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

S. Grant, R. Decker, M. Ehinger, 1999, Oncogene.

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

S. Bates, S. Grant, R. Johnstone, 2012, Epigenomics.

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

S. Grant, M. Egorin, J. Wright, 2009, Clinical Cancer Research.

Cancer Therapy : Clinical Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

S. Grant, M. Egorin, J. Wright, 2009 .

HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells

P. Dent, S. Grant, N. Cruickshanks, 2014, Cancer biology & therapy.

Histone deacetylase inhibitors and rational combination therapies.

S. Grant, Yun Dai, 2012, Advances in cancer research.

Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells.

S. Grant, R. Rosato, E. Battaglia, 2005, International journal of oncology.

Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1

S. Grant, Yun Dai, X. Pei, 2009, Molecular and Cellular Biology.

The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.

P. Atadja, S. Payne, S. Spiegel, 2006, Molecular pharmacology.

Romidepsin for the treatment of non-Hodgkin’s lymphoma

S. Grant, V. Yazbeck, 2015, Expert opinion on investigational drugs.

Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

S. Grant, Yun Dai, P. Bose, 2014, Pharmacology & therapeutics.

Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death

P. Dent, A. Yacoub, S. Grant, 2011, Cancer biology & therapy.

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells

P. Atadja, P. Dent, S. Grant, 2005, Molecular Cancer Therapeutics.

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

John D. Roberts, G. Shapiro, S. Grant, 2013, Clinical Cancer Research.

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Elizabeth B. Collins, John D. Roberts, S. Dave, 2020, Leukemia & lymphoma.

Rational Combinations of Targeted Agents in AML

S. Grant, P. Bose, 2015, Journal of clinical medicine.

Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition

S. Grant, B. Holkova, P. Bose, 2014 .

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.

P. Dent, S. Grant, M. Rahmani, 2004, Blood.

Pazopanib and HDAC inhibitors interact to kill sarcoma cells

P. Dent, S. Grant, A. Poklepovic, 2014, Cancer biology & therapy.

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy

P. Dent, S. Grant, N. Cruickshanks, 2013, Cancer biology & therapy.

The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.

Paul Dent, Hisashi Harada, Andrea Ferreira-Gonzalez, 2009, Blood.

The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells

S. Grant, X. Pei, Y. Dai, 2003, Leukemia.

different immunosuppressive regimens Changes in T-cell receptor VB repertoire in aplastic anemia : effects of

E. Solary, S. Grant, M. Fontenay, 2002 .

Recruiting TP53 to target chronic myeloid leukemia stem cells

S. Grant, 2020, Haematologica.

Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies

S. Grant, 2018, Leukemia & lymphoma.

A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2*

Yun Dai, Paul Dent, Seth J Corey, 2004, Journal of Biological Chemistry.

Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.

P. Dent, S. Grant, Tri K. Nguyen, 2006, Leukemia research.

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations

S. Grant, Yun Dai, C. Dumur, 2014, Leukemia.

The Impact of Molecularly Targeted Therapy in Multi-Modality Therapy

P. Dent, S. Grant, Shiyu Song, 2009 .

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

K. Pradhan, S. Demo, A. Verma, 2023, Research square.

Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes

P. Dent, S. Grant, S. Han, 2004, Hepatology.

Update on rational targeted therapy in AML.

S. Grant, D. Shafer, 2016, Blood reviews.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.

P. Dent, S. Grant, Yun Dai, 2003, Molecular pharmacology.

MDA-7 regulates cell growth and radiosensitivity in vitro of primary (Non-Established) human glioma cells

P. Fisher, P. Dent, A. Yacoub, 2004, Cancer biology & therapy.

Radiotherapy-induced signal transduction.

P. Fisher, P. Dent, M. Hagan, 2006, Endocrine-related cancer.

farnesylation and activation lethality in human leukemia and myeloma cells by disrupting Ras Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01)

P. Dent, S. Grant, Yun Dai, 2013 .

BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress

J. Friedberg, R. Fisher, P. Dent, 2009, Cancer biology & therapy.

Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.

P. Dent, S. Grant, Yun Dai, 2007, Blood.

Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process

E. Sausville, P. Dent, S. Grant, 2004, Oncogene.

MEK1/2 Inhibitors Promote Ara-C-Induced Apoptosis but Not Loss of ΔΨm in HL-60 Cells

P. Dent, S. Grant, Chunrong Yu, 2001 .

Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells

S. Grant, Wenming Chen, Liang Zhou, 2022, Hematological oncology.

MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.

P. Dent, S. Grant, H. Harada, 2007, Blood.

Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.

P. Dent, S. Grant, Yun Dai, 2002, Blood.

Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L).

S. Grant, Yun Dai, Zhiliang Wang, 2002, The Journal of pharmacology and experimental therapeutics.

Inhibitors of MEK1/2 Interact with UCN-01 to Induce Apoptosis and Reduce Colony Formation in Mammary and Prostate Carcinoma Cells

P. Dent, A. Yacoub, S. Grant, 2002, Cancer biology & therapy.

Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).

P. Dent, S. Grant, L. Boise, 2000, Biochemical pharmacology.

mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

P. Fisher, P. Dent, S. Grant, 2006, Pharmacology & therapeutics.

Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737

Dongmin Gu, S. Grant, Richard J. Jones, 2014, PloS one.

Cyclin kinase inhibitor p21 potentiates bile acid–induced apoptosis in hepatocytes that is dependent on p53

P. Fisher, P. Dent, S. Grant, 2002, Hepatology.

Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs

P. Dent, S. Grant, N. Cruickshanks, 2014, Molecular Cancer Therapeutics.

Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling

S. Spiegel, P. Dent, S. Grant, 2012, Cancer biology & therapy.

Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes.

J. Grandis, P. Dent, A. Yacoub, 2005, Biochemical pharmacology.

Apoptotic Response of Hepatocytes-Terminal Kinase Pathways , Modulates the 2 Signal-Regulated Kinase and c-Jun NH c-Jun Function , via the Extracellular , CREB , and β Bile Acid Regulation of C / EBP

P. Dent, K. Valerie, G. Amorino, 2003 .

Functional Antagonism of Human CD40 Achieved by Targeting a Unique Species-Specific Epitope.

A. Yamniuk, S. Sheriff, S. Grant, 2016, Journal of molecular biology.

Histone Deacetylase Inhibitors and Anticancer Activity

S. Grant, R. Rosato, 2008 .

Pharmocologic Inhibitors of the Mitogen Activated Protein Kinase Cascade Have the Potential to Interact with Ionizing Radiation Exposure to Induce Cell Death in Carcinoma Cells by Multiple Mechanisms

P. Fisher, P. Dent, M. Hagan, 2002, Cancer biology & therapy.

Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis.

P. Fisher, P. Nagarkatti, R. Schmidt-Ullrich, 2001, Molecular biology of the cell.

Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways

G. Duigou, C. S. Young, P. Fisher, 2001, Oncogene.

Modulation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in L1210 cells by fluoropyrimidine pretreatment.

S. Grant, E. Cadman, 1982, Cancer research.

RETRACTION: Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells That Overexpress Bcl-2

S. Grant, G. Dasmahapatra, J. Almenara, 2006, Molecular Pharmacology.

Histone deacetylase inhibitors: insights into mechanisms of lethality

S. Grant, R. Rosato, 2005, Expert opinion on therapeutic targets.

In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells

S. Grant, Simon S. Jones, S. Quayle, 2014, Molecular Cancer Therapeutics.

Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

J. Friedberg, R. Fisher, P. Dent, 2011, Molecular Cancer Therapeutics.

Mantle cell lymphoma: biological insights and treatment advances.

J. Leonard, M. Pfreundschuh, S. Grant, 2009, Clinical lymphoma & myeloma.

Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).

P. Dent, S. Grant, S. Wang, 1998, Biochemical pharmacology.

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

S. Grant, Yun Dai, Lora B. Kramer, 2019, Journal of Hematology & Oncology.

Disruption of IκB Kinase (IKK)-mediated RelA Serine 536 Phosphorylation Sensitizes Human Multiple Myeloma Cells to Histone Deacetylase (HDAC) Inhibitors*

P. Dent, S. Grant, Yun Dai, 2011, The Journal of Biological Chemistry.

Exploiting cellular pathways to develop new treatment strategies for AML.

S. Grant, J. Karp, A. Fathi, 2010, Cancer treatment reviews.

The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.

S. Grant, R. Rosato, J. Almenara, 2007, Cancer research.

LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

P. Dent, S. Grant, R. Rosato, 2012, Leukemia research.

Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

S. Grant, M. Rahmani, B. Holkova, 2017, Oncotarget.

Orphan drug designation for pracinostat, volasertib and alvocidib in AML.

S. Grant, P. Bose, 2014, Leukemia research.

Minting a new class of Polo-like-kinase inhibitors

P. Fisher, P. Dent, S. Grant, 2009, Cancer biology & therapy.

Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes

P. Dent, S. Grant, Weiqun Li, 2004, Hepatology.

Acid Ceramidase (ASAH1) Mediates Intrinsic and Intercellular Transfer of Proteasome Inhibitor Resistance in Multiple Myeloma

O. Hampton, S. Grant, K. Shain, 2021, Blood.

Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.

S. Grant, Zhiliang Wang, Shujie Wang, 2003, Molecular pharmacology.

Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.

P. Dent, S. Grant, 2007, Current drug targets.

Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells

P. Fisher, P. Dent, S. Grant, 2013, Cancer biology & therapy.

Histone Deacetylase Inhibitors Interact with Melanoma Differentiation Associated-7/Interleukin-24 to Kill Primary Human Glioblastoma Cells

P. Fisher, P. Dent, A. Yacoub, 2013, Molecular Pharmacology.

The development of MDA-7/IL-24 as a cancer therapeutic.

P. Fisher, P. Dent, A. Yacoub, 2010, Pharmacology & therapeutics.

MDA-7/IL-24 as a cancer therapeutic: from bench to bedside

P. Fisher, P. Dent, A. Yacoub, 2010, Anti-cancer drugs.

OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins

P. Fisher, P. Dent, A. Yacoub, 2010, Cancer biology & therapy.

Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma Differentiation-Associated Gene-7/Interleukin-24–Induced Killing in Ovarian Carcinoma Cells

P. Fisher, P. Dent, A. Yacoub, 2010, Molecular Pharmacology.

MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism

P. Fisher, S. Spiegel, P. Dent, 2009, Molecular Cancer Therapeutics.

Cisplatin enhances PERK- and CD95-dependent MDA-7/IL-24-induced killing in ovarian carcinoma cells

P. Fisher, P. Dent, A. Yacoub, 2009 .

Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.

P. Fisher, N. Senzer, J. Nemunaitis, 2007, Toxicology and applied pharmacology.

mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review).

S. Inoue, P. Fisher, R. Ramesh, 2007, International journal of oncology.

MDA‐7/IL‐24 regulates proliferation, invasion and tumor cell radiosensitivity: A new cancer therapy?

Paul Dent, P. Fisher, P. Dent, 2005, Journal of cellular biochemistry.

Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo.

P. Fisher, P. Dent, A. Yacoub, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

mda-7 (IL-24) Inhibits Growth and Enhances Radiosensitivity of Glioma Cells In Vitro via JNK Signaling

P. Fisher, P. Dent, A. Yacoub, 2003, Cancer biology & therapy.

Lapatinib and Obatoclax Kill Tumor Cells through Blockade of ERBB1/3/4 and through Inhibition of BCL-xL and MCL-1

P. Fisher, P. Dent, S. Grant, 2012, Molecular Pharmacology.

Regulation of autophagy by ceramide-CD95-PERK signaling

P. Fisher, P. Dent, S. Grant, 2008, Autophagy.

Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms

P. Houghton, P. Dent, A. Yacoub, 2009, Molecular Pharmacology.

BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing

A. Thorburn, D. Häussinger, P. Dent, 2009, Molecular Pharmacology.

Searching for a cure: Gene therapy for glioblastoma

P. Fisher, K. Shah, P. Dent, 2008, Cancer biology & therapy.

OSU-03012 Stimulates PKR-Like Endoplasmic Reticulum-Dependent Increases in 70-kDa Heat Shock Protein Expression, Attenuating Its Lethal Actions in Transformed Cells

P. Fisher, S. Spiegel, P. Dent, 2008, Molecular Pharmacology.

OSU-03012 Promotes Caspase-Independent but PERK-, Cathepsin B-, BID-, and AIF-Dependent Killing of Transformed Cells

P. Dent, A. Yacoub, S. Grant, 2006, Molecular Pharmacology.

Lapatinib and Obatoclax Kill Breast Cancer Cells through Reactive Oxygen Species-Dependent Endoplasmic Reticulum Stress

P. Dent, S. Grant, N. Cruickshanks, 2012, Molecular Pharmacology.

Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells

P. Dent, S. Grant, Yukihiro Yamaguchi, 2013, Journal of cellular physiology.

Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.

S. Grant, M. Rahmani, A. Ferreira-Gonzalez, 2012, Blood.

A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy

Khaled M. Elokely, S. Grant, D. Altieri, 2017, Oncotarget.

Augmenting Venetoclax Activity Through Signal Transduction in AML

S. Grant, Ian M. Bouligny, Keri R Maher, 2023, Journal of cellular signaling.

The BH 3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI 3 K / Akt and MEK / ERK 1 / 2 pathways

P. Dent, S. Grant, H. Harada, 2009 .

BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance

S. Grant, Yun Dai, 2015, Autophagy.

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells

S. Grant, Liang Zhou, Xiaoyan Hu, 2023, Hematology reports.

Functional role of DNMT1 in the anti-leukemic effects of hypomethylating agents in AML cells.

S. Grant, Liang Zhou, Xiaoyan Hu, 2022, Leukemia research.

Fractal Organization of the Human T Cell Repertoire in Health and Following Stem Cell Transplantation

C. Desmarais, C. Sanders, S. Grant, 2012 .

Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.

John D. Roberts, M. Andreeff, S. Grant, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte‐macrophage progenitors to recombinant GM‐CSF

J. Staniswalis, S. Grant, C. McCrady, 1991, British journal of haematology.

A chicken-or-egg conundrum in apoptosis: which comes first? Ceramide or PKCdelta?

S. Spiegel, S. Grant, 2002, The Journal of clinical investigation.

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia

N. Wages, S. Grant, Yanal Alnimer, 2023, EJHaem.

Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors.

S. Grant, D. Gewirtz, E. Feldman, 1991, Leukemia.

Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation

S. Grant, M. Rahmani, C. Dumur, 2015, Haematologica.

Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma.

H. Fu, S. Grant, Yuhong Du, 2013, Organic & biomolecular chemistry.

Biological Characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a Selective Sphingosine Kinase-2 Inhibitor and Anticancer Agent

Hardik I. Parikh, S. Spiegel, G. Kellogg, 2013, PloS one.

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

S. Grant, P. Bose, 2013, Leukemia research reports.

Potentiation of 1-β- d-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01) ∗ ∗ Portions of this work have been reported in preliminary form at the Meeting for the American Ass

P. Dent, S. Grant, L. Boise, 2000 .

Inhibition of the MAPK and PI3K pathways enhances UDCA‐induced apoptosis in primary rodent hepatocytes

P. Dent, A. Yacoub, S. Grant, 2002, Hepatology.

c-kit expression by CD34+ bone marrow progenitors and inhibition of response to recombinant human interleukin-3 following exposure to c-kit antisense oligonucleotides

S. Grant, E. Westin, J. Leftwich, 1991 .

Experimental design and statistical analysis for three-drug combination studies

Hong-Bin Fang, Xuerong Chen, Ming Tan, 2017, Statistical methods in medical research.

Δ9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria

M. Nagarkatti, P. Nagarkatti, S. Grant, 2006, Molecular Cancer Research.

malignant lymphoblastic disease Targeting CB2 cannabinoid receptors as a novel therapy to treat

Michael T. Fisher, M. Nagarkatti, P. Nagarkatti, 2013 .

Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.

Michael T. Fisher, M. Nagarkatti, P. Nagarkatti, 2002, Blood.

Approaches for monitoring signal transduction changes in normal and cancer cells.

P. Fisher, P. Dent, S. Grant, 2007, Methods in molecular biology.

7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism.

P. Dent, P. Lin, S. Grant, 2002, International journal of oncology.

MEK Inhibitors Potentiate Dexamethasone Lethality in Acute Lymphoblastic Leukemia Cells through the Pro-apoptotic Molecule BIM

S. Grant, H. Harada, Lora B. Kramer, 2009, Leukemia.

Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.

P. Dent, M. Hagan, A. Yacoub, 2005, Molecular cancer therapeutics.

Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms

S. Grant, M. Rahmani, M. Aust, 2013 .

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B‐cell Lymphoma

John D. Roberts, C. Flowers, D. Coppola, 2018, Clinical lymphoma, myeloma & leukemia.

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.

J. Friedberg, R. Fisher, P. Dent, 2010, Blood.

The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.

P. Dent, S. Grant, M. Rahmani, 2004, Cell cycle.

RAC3 down‐regulation sensitizes human chronic myeloid leukemia cells to TRAIL‐induced apoptosis

S. Grant, R. Rosato, M. Costas, 2007, FEBS letters.

Targeting Histone Demethylases in Cancer Therapy

S. Grant, 2009, Clinical Cancer Research.

Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts)

Angelika M. Burger, Maria R. Baer, Merrill J. Egorin, 2008 .

AND HISTONE DEACETYLASE INHIBITORS PROMOTE MITOCHONDRIAL INJURY AND CELL DEATH IN HUMAN LEUKEMIA CELLS OVEREXPRESSING BCL-2

S. Grant, G. Dasmahapatra, 2005 .

Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells

S. Grant, Liang Zhou, Xiaoyan Hu, 2023, Cellular Oncology.

Phase I clinical and pharmacologic study of deoxycytidine.

K. Bhalla, S. Grant, M. Baker, 1988, Leukemia.

Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

J. Friedberg, R. Fisher, P. Dent, 2019, Molecular Cancer Therapeutics.

Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo

P. Dent, A. Yacoub, S. Grant, 2008, Cancer biology & therapy.

The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.

S. Grant, M. Rahmani, Yun Dai, 2002, Experimental cell research.

DMC: Novel celecoxib derivatives to rap cancer

P. Dent, A. Yacoub, S. Grant, 2005, Cancer biology & therapy.

The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.

K. Bhalla, S. Grant, Z. Arlin, 1990, Experimental hematology.

Induction of apoptotic DNA fragmentation and c-jun downregulation in human myeloid leukemia cells by the permeant Ca2+ chelator BAPTA/AM.

R. Mikkelsen, S. Grant, W. Jarvis, 1995, Oncology research.

Current advances in ER stress intervention therapies

P. Fisher, P. Dent, S. Grant, 2012 .

Modulation by bryostatin 1 of the in vitro radioprotective effects of the GM-CSF/IL-3 fusion protein, PIXY 321, on normal human myeloid progenitors.

P. Lin, S. Grant, G. Pettit, 1993, Cytokine.

The role of ceramide in the cellular response to cytotoxic agents.

S. Grant, W. Jarvis, 1998, Current opinion in oncology.

LCL161 interacts synergystically with panobinostat in multiple myeloma cells through non-canonical NF-κB- and caspase-8-dependent mechanisms.

S. Grant, Yun Dai, Lora B. Kramer, 2021, Blood advances.

myeloma cells through an IL-6-independent mechanism inhibitors potently induces apoptosis in drug-sensitive and-resistant Combined treatment with the checkpoint abrogator UCN-01 and MEK 1

P. Dent, S. Grant, S. Rosen, 2002 .

OSU-03012 interacts with lapatinib to kill brain cancer cells

P. Dent, S. Grant, N. Cruickshanks, 2012, Cancer biology & therapy.

Radiation-Stimulated ERK1/2 and JNK1/2 Signaling can Promote Cell Cycle Progression in Human Colon Cancer Cells

P. Dent, M. Hagan, A. Yacoub, 2005, Cell cycle.

Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM).

S. Grant, G. Pettit, C. McCrady, 1992, Experimental hematology.

The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01–Induced Apoptosis in Human Multiple Myeloma Cells

P. Dent, S. Grant, M. Rahmani, 2005, Clinical Cancer Research.

Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression.

P. Dent, J. Park, A. Yacoub, 2001, Hepatology.

Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?

S. Grant, P. Bose, 2012, Expert review of hematology.

Conversion of Drug-Induced Differentiation to Apoptosis by Pharmacologic Cyclin-Dependent Kinase Inhibitors

P. Dent, S. Grant, 2002, Cell cycle.

Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

G. Kellogg, S. Grant, S. T. Eblen, 2009, Bioorganic & medicinal chemistry letters.

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Sara W. Bird, Erinna F. Lee, Michael D. Kim, 2016 .

Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik

S. Grant, Richard J. Jones, R. Orlowski, 2014, Molecular and Cellular Biology.

MEK1/2 inhibition promotes Taxotere® lethality in mammary tumors in vivo

P. Fisher, P. Dent, M. Hagan, 2006, Cancer biology & therapy.

Sequence Dependent Exposure of Mammary Carcinoma Cells to Taxotere® and the MEK1/2 Inhibitor U0126 Causes Enhanced Cell Killing In Vitro

P. Dent, A. Yacoub, R. Carón, 2003, Cancer biology & therapy.

R-spondin(g) to syndecan-1 in myeloma.

S. Grant, 2018, Blood.

Diseases Antibody for Treatment of Autoimmune Engineering of a Novel Anti-CD 40 L Domain

A. Yamniuk, S. Grant, J. Bryson, 2014 .

Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells.

P. Dent, S. Grant, Zhiliang Wang, 2003, Blood.

A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1.

S. Grant, M. Carr, S. Carr, 1995, Anti-cancer drugs.

Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.

S. Grant, W. Jarvis, V. Joe, 1994, Oncology research.

Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies

S. Grant, J. Lancet, M. Rudek, 2023, Cancer Chemotherapy and Pharmacology.

The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?

S. Grant, 2004, Leukemia.

Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652

Lee, Duchen, Izzo, 2016 .

Augmentation of intracellular cytosine arabinoside accumulation and effect by thymidine in l1210 cells. Abstr.

S. Grant, E. Cadman, I. Goldenberg, 1979 .

Deoxycytidine stimulates the in vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and prostaglandin E1.

K. Bhalla, S. Grant, Z. Arlin, 1986, Blood.

cells sensitive and resistant to STI-571 in association with down-regulation of Bcr- Abl, abrogation of STAT5 activity, and Bax conformational change.

R. Jove, Meijuan Huang, P. Dent, 2004 .

Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022

S. Grant, Ian M. Bouligny, Keri R Maher, 2023, Cancers.

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

S. Grant, M. Kmieciak, Elisa Hawkins, 2018, BMC Cancer.

The BH3-only protein Bim plays a critical role in cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK pathways in human leukemia cells

P. Dent, S. Grant, M. Rahmani, 2008 .

Editor's Note: Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs

P. Dent, S. Grant, N. Cruickshanks, 2019, Molecular Cancer Therapeutics.

Abstract 796: Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy

P. Dent, S. Grant, N. Cruickshanks, 2014 .

Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.

K. Bhalla, S. Grant, G. Pettit, 1992, Leukemia.

Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.

S. Grant, G. Pettit, C. McCrady, 1991, Leukemia.

Abstract 4836: Targeting transcriptional regulation in multiple myeloma with a covalent CDK7 inhibitor THZ1

S. Grant, Liang Zhou, Jacquelyn McCarter, 2018, Experimental and Molecular Therapeutics.

Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways

G. Duigou, C. S. Young, P. Fisher, 2001, Oncogene.

The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib.

J. Friedberg, R. Fisher, S. Grant, 2012 .

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

N. Wages, S. Grant, T. Ho, 2023, Research square.

Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.

S. Grant, S. Yanovich, A. Turner, 1995, Leukemia.

Cell cycle regulation and hematologic disorders.

S. Grant, Yun Dai, P. Bose, 2016 .

Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.

Michael L. Wang, P. Dent, S. Grant, 2009 .

GLS Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth when Combined with 5-Azacitidine

D. Rakheja, M. Konopleva, A. Verma, 2016 .

Differentiation therapy of human cancer: basic science and clinical applications.

P. Fisher, P. Dent, S. Grant, 2001, Pharmacology & therapeutics.

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

The epigenetic regulation of cancer cell recovery from therapy exposure and its implications as a novel therapeutic strategy for preventing disease recurrence.

H. Bear, P. Dent, S. Grant, 2023, Advances in cancer research.

Different N-Terminal Motifs Determine Plasma Membrane Targeting of the Human Concentrative Nucleoside Transporter 3 in Polarized and Nonpolarized Cells

S. Hammond, Takafumi Hara, G. Tsujimoto, 2010, Molecular Pharmacology.

Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy

S. Milstien, S. Spiegel, S. Grant, 2012, Oncogene.

The kinase inhibitor sorafenib induces cell death through a process involving induction of ER stress

P. Dent, S. Grant, M. Rahmani, 2007 .

Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment

John D. Roberts, P. Fisher, P. Dent, 2007, Molecular Pharmacology.

Association of p93c-fes tyrosine protein kinase with granulocytic/monocytic differentiation and resistance to differentiating agents in HL-60 leukemia cells.

G. Yu, R. Glazer, S. Grant, 1988, Molecular Pharmacology.

Ceramide and the induction of apoptosis.

S. Grant, R. Kolesnick, W. Jarvis, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting novel signaling pathways for resistant acute myeloid leukemia.

L. Platanias, S. Grant, K. Sakamoto, 2015, Molecular genetics and metabolism.

THE MULTIKINASE INHIBITOR SORAFENIB INDUCES APOPTOSIS IN HIGHLY IMATINIB MESYLATE-RESISTANT BCR/ABL + HUMAN LEUKEMIA CELLS IN ASSOCIATION WITH STAT5 INHIBITION AND MCL-1 DOWN-REGULATION

P. Dent, S. Grant, M. Rahmani, 2007 .

Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.

P. Fisher, P. Dent, A. Yacoub, 2010, Cancer research.

Searching for a cure: Gene therapy for glioblastoma

P. Fisher, K. Shah, P. Dent, 2008, Cancer biology & therapy.

Bortezomib for the treatment of non-Hodgkin’s lymphoma

S. Grant, B. Holkova, P. Bose, 2014, Expert opinion on pharmacotherapy.

Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo

John D. Roberts, P. Dent, M. Hagan, 2008, Molecular Cancer Therapeutics.

Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.

S. Grant, M. Rahmani, A. Ferreira-Gonzalez, 2013, Cancer research.

Lapatinib and Obatoclax Kill Breast Cancer Cells through Reactive Oxygen Species-Dependent Endoplasmic Reticulum Stress

P. Dent, S. Grant, Yong Tang, 2012, Molecular Pharmacology.

Experimental design and statistical analysis for three-drug combination studies

M. Tan, Hong-Bin Fang, S. Grant, 2017, Statistical methods in medical research.

BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing

A. Thorburn, D. Häussinger, P. Dent, 2009, Molecular Pharmacology.

Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms

P. Houghton, P. Dent, A. Yacoub, 2009, Molecular Pharmacology.

Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma

S. Grant, R. Orlowski, Yun Dai, 2017, Oncotarget.

Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF‐κB and Bim

P. Dent, S. Grant, Yun Dai, 2011, British journal of haematology.

Is the focus moving toward a combination of targeted drugs?

S. Grant, 2008, Best practice & research. Clinical haematology.

Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF-κB Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun N-Terminal Kinase 1 Activation

P. Dent, S. Grant, M. Rahmani, 2005, Molecular and Cellular Biology.

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.

E. Sausville, P. Dent, S. Grant, 2003, Blood.

Characterization of compounds shed from the surface of human leukemic myeloblasts in vitro

S. Grant, T. Mohanakumar, D. Roncari, 1982 .

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

S. Grant, A. Berger, L. Povirk, 2016, Blood.

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

R. Larson, Helen X. Chen, C. Hourigan, 2022, Blood.

A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.

Barbara S. Paugh, S. Milstien, S. Spiegel, 2008, Blood.

Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24–mediated toxicity

P. Fisher, John Calvin Reed, P. Dent, 2011, Proceedings of the National Academy of Sciences.

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

P. Dent, S. Grant, Yun Dai, 2008, Blood.

Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cellsin vitroandin vivo

S. Grant, Yun Dai, Lora B. Kramer, 2011 .

Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism

S. Grant, Tri K. Nguyen, 2013, Molecular Cancer Therapeutics.